studies of early CP intervention starting at 6 months of age have been ongoing since 2013. A limitation to the generalizability of our findings may be that 3 clinical trials of early CP motor interventions have been ongoing since 2013.
), receipt of a systemic antibiotic potentially prescribed for CAP (penicillins with or without β-lactamase inhibitors, cephalosporins, carbapenems, macrolides, doxycycline, fluoroquinolones, vancomycin, linezolid, clindamycin, or trimethoprim-sulfamethoxazole), and an overnight stay. We excluded children with complex chronic conditions, 5 severe and/or complicated CAP (hospitalized >7 days; effusion, empyema, or lung abscess; 2 consecutive days of mechanical ventilatory assistance or vasopressor use; or extracorporeal membrane oxygenation), and infection, colonization, or history of methicillin-resistant Staphylococcus aureus. Premier Perspectives contains deidentified data, and PHIS data are not readily identifiable. The Children's Hospital of Philadelphia Institutional Review Board has determined that analysis using PHIS is not human subjects research.
To distinguish children's hospitals from non-children's hospitals in Premier Perspectives, we applied a definition informed by PHIS using the observed minimum proportion of all discharges (≥1 year of age) that were for children (PHIS minimum during study period, 49%; Premier Perspectives hospitals with ≥49% were classified as children's hospitals). Two Premier Perspectives children's hospitals were identified as likely duplicates of PHIS hospitals based on census region, annual discharges, and annual CAP cases and were excluded. Using a longitudinal piecewise logistic model with a knot at October 2011 (guideline publication), we modeled the linear trajectory of guideline-concordant prescribing (defined as receipt of any penicillin, amoxicillin, or ampicillin during admission) before and after publication, stratified by hospital type (children's vs non-children's). Potential confounders (age, sex, and insurance payer) did not meaningfully affect model estimates and were excluded from the final model. We adjusted SEs for clustering by hospital. Probabilities of guidelineconcordant prescribing with 95% CIs were calculated (CI by Δ method) from the fitted model. Two-sided P < .05 from Wald tests was considered statistically significant. . At both hospital types, the trajectory of guideline-concordant prescribing changed after guideline release ( Figure) . In children's hospitals, the modeled probability of guidelineconcordant prescribing increased from 0.25 (95% CI, 0.15-0.34) immediately before guideline release to 0.61 (95% CI, 0.56-0.66) at study end. If the preguideline trajectory had been maintained without the observed change after guideline release, the probability of guideline-concordant prescribing would have been 0.31 (95% CI, 0.15-0.47; P = .001) at study end. In non-children's hospitals, the probability of guidelineconcordant prescribing increased from 0.06 (95% CI, 0.04-0.08) immediately before guideline release to 0.27 (95% CI, 0.20-0.35) at study end. If the preguideline trajectory had continued, prescribing would have been 0.08 (95% CI, 0.01-0.14; P = .004) at study end. Postguideline trajectories were similar between hospital types (difference in probability from beginning to end of final study year: 0.08 absolute increase [95% CI, 0.05-0.10] at children's hospitals vs 0.07 absolute increase [95% CI, 0.04-0.10] at non-children's hospitals; P = .56).
Results
Discussion | Four years after publication of national pediatric CAP guidelines, only 27% of children admitted to non-children's hospitals received guideline-concordant therapy compared with 61% in children's hospitals. This gap is concerning because approximately 70% of children hospitalized with pneumonia receive care in non-children's hospitals. 6 The reason for this difference in guideline-concordant prescribing is unknown. It is unlikely attributable to differences in patient populations because we included only healthy children with uncomplicated CAP and adjusted for potential confounders. Studies 3 in children's hospitals have suggested that local implementation efforts may be important in facilitating guideline uptake. Non-children's hospitals likely have fewer resources to lead pediatric-specific efforts, and care may be influenced by adult CAP guidelines. Our study is limited by the use of administrative data, potential unknown discrepancies between the databases, and absence of a children's hospital indicator in Premier Perspectives. However, we identified patients with a validated algorithm, and our results were consistent with prior work in both databases.
3,6 Although guideline-concordant prescribing has increased in both children's and nonchildren's hospitals, non-children's hospitals appear to be lagging markedly behind children's hospitals. This discrepancy may represent an important target for antimicrobial stewardship efforts. 
Prevalence of Cannabis Use in Youths After Legalization in Washington State
In November 2012, voters in Washington legalized nonmedical (retail) cannabis for people aged 21 and older. Markets opened in July 2014. The effect of this change on cannabis use among youths is of public health concern. Cerdá et al 1 analyzed data from the nationally representative Monitoring the Future survey (MTF) and used differencein-differences methods to compare cannabis use prevalence trends among youths in Washington with use in states without legalization of recreational marijuana. Because the MTF is not designed to provide state-representative estimates, the article generated covariate-adjusted modeled prevalence estimates for each state. The article suggested complex association between legalization and cannabis use among youths: increases in prevalence among Washington 8th and 10th graders, but not among 12th graders, relative to use in states without legalization of recreational marijuana. The authors noted that, "the sample design may lead to discrepancies between MTF results and those found in other large-scale surveillance efforts." 1(p148) The purpose of the present study was to assess whether trends in cannabis use prevalence among youths from Washington's state-based youth survey are consistent with findings from the MTF. 2014 -2016 combined (MTF reported 2013 -2015 . Significance was established at P < .05 with unpaired, 2-tailed testing. Analysis was conducted using Stata, version 14.2 (StataCorp).
Results | More schools and students are captured in the HYS than MTF (Table) . cannabis use were added using z scores. c P values from χ 2 tests for school and student characteristics, and from logistic regression for youth cannabis use by period (eg, either 2014 or 2014-2016 vs 2010-2012) . d P values for school/student characteristics based on z scores for cannabis use. 1 e Low SES based on mother's highest level of educational level less than high school graduate.
